Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.

The Long Run with Luke Timmerman

Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep190: Neil Kumar on Building a Rare Disease Drug Company

Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI

Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Ep188: Art Krieg on Innate Immune System Activators for Cancer

Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.

Ep187: Eric Fischer on Creating a New Class of Medicines

Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.

Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale

Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies

Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.

Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science

Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.

Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer

Scienze

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.